New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 1, 2014
07:22 EDTINCYIncyte reports Q1 EPS (21c), consensus (18c)
Reports Q1 total revenues $89.8M, consensus $97.19M. The company said, "The increase in net loss in Q1 as compared to the same period of 2013 is primarily due to the company’s broad investment in its clinical pipeline and additional costs related to the commercialization of Jakafi in MF and preparation for the anticipated launch in PV."
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
07:52 EDTINCYIncyte reinstated with a Buy at BofA/Merrill
Subscribe for More Information
May 27, 2015
07:33 EDTINCYIncyte says clinical portfolio to be featured in 23 abstract presentations
Incyte Corporation (INCY) announced that 23 abstracts detailing studies from its clinical development pipeline, including those conducted by Incyte, Novartis (NVS) and independent investigators, will be presented at the 2015 American Society of Clinical Oncology and European Hematology Association annual meetings. These conferences will take place from May 29th – June 2nd in Chicago, IL and June 11th – 14th in Vienna, Austria. “The abstracts to be presented at ASCO and EHA showcase the depth and breadth of our development pipeline in oncology, as well as the success of our collaboration with Novartis,” stated Rich Levy, MD, Incyte’s Chief Drug Development Officer. “Incyte is committed to translating R&D excellence into new medicines which can improve patients’ lives, and these data, including novel:novel combinations from within our portfolio, provide further evidence of our ongoing progress.”
May 19, 2015
07:22 EDTINCYIncyte has a conference call hosted by JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use